NCI60 anticanc[illegible]rug discov[illegible]program was revi[illegible]d in detail by Shoemaker, wh[illegible]ghlighted [illegible]istory and metho[illegible]gy. Learning from the NCI60 [illegible]periences, t[illegible]Cancer Chemother[illegible]Center of the Japanese Found[illegible]n for Can[illegible]Research establis[illegible]the JFCR-39 platform. This p[illegible]l of 39 hu[illegible] tumour-derived c[illegible]lines included a subset of the [illegible]CI60 cell li[illegible] and additional g[illegible]c cancer cell lines. A new a[illegible]thm for da[illegible]nalysis enabled t[illegible]omparison of newly screened [illegible]mpounds w[illegible]previously screen[illegible]ompounds to discriminate be[illegible]en new or [illegible]viously described [illegible]les of action. Using the COM[illegible]RE algorith[illegible]d advanced data n[illegible]g techniques, several new an[illegible]ncer agents[illegible]re identified. In c[illegible] discovery or predictive biom[illegible]er studies [illegible]the introduced ta[illegible]ed anticancer therapeutics', s[illegible]l panels o[illegible]ncer cell lines ca[illegible]t display the clinical activitie[illegible] these comp[illegible]ds, which are ofte[illegible]mited to small subgroups of m[illegible]ular-define[illegible]ients [15]. Taking[illegible] into account, high-throughpu[illegible]reenings a[illegible]ow being adapte[illegible] much larger panels of cell li[illegible]

Discussion

To capture [illegible] genetic het[illegible]geneity among div[illegible] cancers, Mc Dermott and c[illegible]agues deve[illegible]ed an automated [illegible]form for the screening of th[illegible]emo-sensit[illegible]y of 500 solid ca[illegible] cell lines to kinase inhibitor[illegible]n this study[illegible]ey observed the e[illegible]cted response rates with onl[illegible]mall subgr[illegible] of cell lines sh[illegible]ng responses to particular c[illegible]ounds. Th[illegible]ore, a comprehen[illegible] cancer cell line platform w[illegible]established,[illegible]rrently including [illegible]0 cancer cell lines [16]. Due[illegible]the fact tha[illegible]y around 80 % o[illegible]se secondary cancer cell line[illegible]re adaptable[illegible]high-throughput s[illegible]ening, mostly caused by tech[illegible]l limitations[illegible]h as insufficient [illegible]bling times or atypical culture[illegible]quirements,[illegible] panel is referred[illegible]as the Center for molecular T[illegible]apeutics 100[illegible]his cell line panel[illegible]urrently being used to invest[illegible]e the genet[illegible]eterminants for c[illegible]o-sensitivity. First results fr[illegible]his large da[illegible]ts showed that tu[illegible]r-derived cell lines recapitula[illegible]clinical find[illegible] concerning resp[illegible]s to targeted inhibitors. And[illegible]r, very recen[illegible]proach in genera[illegible] primary cell lines for in vit[illegible]xperiments [illegible]been introduced [illegible]ui.23 Tm[( )] TJET[illegible]2-2(2)7(0[illegible]0)-6( )-1[illegible])BT-6(r)[illegible]1 93.35 T[illegible]BT1 0[illegible] 54.24 460.

[illegible]it9BT64.[illegible]JETB[illegible]6.532T 0 1 4i[illegible]o2.48 ck11(8[illegible]M15(in[illegible]ET[illegible]ng[illegible]0([illegible]20)1[illegible]4(%)6

17. Secretan BL, Scoccianti C (2015). Breast-cancer screening viewpoint of the IARC Working Group. N Engl J Med US 372:2353-2358.

18. Schwartz LM, Woloshin S, Fowler FJ, Welch HG (2004) Enthusiasm for Cancer Screening in the United States. JAMA US 291:71-78.

19. McKinney SM, Sieniek M, Godbole V, Godwin J (2020). International evaluation of an AI system for breast cancer screening. Nature 577:89-94.

20. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, et al. (1986) Lung cancer screening: the Mayo program. J Occup Med US 28:746-750.